| Budget Amount *help |
¥210,340,000 (Direct Cost: ¥161,800,000、Indirect Cost: ¥48,540,000)
Fiscal Year 2017: ¥40,560,000 (Direct Cost: ¥31,200,000、Indirect Cost: ¥9,360,000)
Fiscal Year 2016: ¥40,560,000 (Direct Cost: ¥31,200,000、Indirect Cost: ¥9,360,000)
Fiscal Year 2015: ¥44,590,000 (Direct Cost: ¥34,300,000、Indirect Cost: ¥10,290,000)
Fiscal Year 2014: ¥44,200,000 (Direct Cost: ¥34,000,000、Indirect Cost: ¥10,200,000)
Fiscal Year 2013: ¥40,430,000 (Direct Cost: ¥31,100,000、Indirect Cost: ¥9,330,000)
|
|---|
| Outline of Final Research Achievements |
Down syndrome is a congenital disease caused by trisomy 21. To elucidate the mechanism of the onset of acute megakaryoblastic leukemia which is frequently occurred in Down's syndrome, novel Down's syndrome model mice and the model human ES cell lines were generated by using our original chromosome engineering technology. Behavioral abnormalities and hematologic abnormalities were observed in the model mice, and haematopoiesis abnormalities were observed in the model human ES cells due to the synergistic effect of trisomy 21 and GATA1 mutation. Furthermore, we succeeded in narrowing down the responsible region on chromosome 21 of the haematopoiesis abnormalities by introducing fragmented human chromosome 21 into human ES cells.
|
